N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntingtonʼs disease mice
- 1 November 2000
- journal article
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 11 (17) , 3751-3757
- https://doi.org/10.1097/00001756-200011270-00032
Abstract
Huntington's disease (HD) is an autosomal dominant condition involving progressive neurodegeneration, primarily the corpus striatum and cerebral cortex. We have used in vivo magnetic resonance spectroscopy (MRS) to assess specific neuronal markers in transgenic mice (R6/1 line) expressing exon I of the human huntingtin gene with an expanded CAG repeat. Levels of N-acetylaspartate (NAA), an indicator of healthy neuronal function, were significantly reduced (26%) in the corpus striatum of HD mice relative to wild-type littermates at 5 months of age. However, levels of cholines and creatine-phosphocreatine were not altered in the HD mice. Expression of dopamine- and cAMP-regulated phosphoprotein, 32 kDa (DARPP-32), was assessed by immunohistochemistry in the striatum of HD mice and found to be downregulated by 5 months and, even more dramatically, at 11 months of age. In contrast, expression of calbindin was not significantly decreased in HD mice. Our results suggest that the observed decreases in DARPP-32 and NAA may contribute to aberrant receptor signalling and neuronal dysfunction in HD.Keywords
This publication has 5 references indexed in Scilit:
- In Vitro Expression of N‐Acetyl Aspartate by OligodendrocytesJournal of Neurochemistry, 2000
- Beyond the Dopamine ReceptorPublished by Elsevier ,1999
- Absolute Quantitation of Water and Metabolites in the Human Brain. II. Metabolite ConcentrationsJournal of Magnetic Resonance, Series B, 1993
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993
- Decreased brain N-acetylaspartate in Huntington's diseaseBrain Research, 1992